Navigation Links
Cempra Inc. Presents Additional Data on the Clinical Profile and Activity Spectrum of Solithromycin at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Date:9/7/2012

CHAPEL HILL, N.C., Sept. 7, 2012 /PRNewswire/ -- Cempra Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that data will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Sept. 9 to 12.  The data will further delineate the clinical profile and activity spectrum of solithromycin, the company's late clinical-stage fluoroketolide antibiotic candidate.  The data demonstrate the promising safety and tolerability profile of solithromycin as well as a pharmacokinetic-pharmacodynamic (PK-PD) analysis that will be used to support Phase 3 intravenous (IV) dose selection.  Solithromycin's activity spectrum was further defined by demonstrating superior activity against Canadian isolates of Neisseria gonorrhoeae compared to azithromycin and the first study investigating solithromycin's activity against Treponema pallidum.   

"Data presented at this year's conference are geared to further detailing the profile of solithromycin from both clinical and activity perspectives," said Prabhavathi Fernandes, president and chief executive officer of Cempra.  "The data should be helpful when we analyze the results from our IV Phase 1 trial, which we expect to complete in the second half of 2012, and our Phase 2 trial in patients with uncomplicated gonococcal infections, which we expect to complete in the fourth quarter of this year, and in the preparation of our Phase 3 program in community-acquired bacterial pneumonia, which we expect to begin in the fourth quarter of this year."

Solithromycin safety and tolerability continues to appear promising

Solithromycin has demonstrated a favorable safety and tolerability profile when compar
'/>"/>

SOURCE Cempra Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UAS Laboratories Presents about Probiotic Selection Criteria, at Scientific Conference
2. Frost & Sullivan Presents 2012 Clinical Diagnostics Company of the Year Award to GenPath Diagnostics of BioReference Laboratories, Inc.
3. Butamax Early Adopters Group surpasses capacity targets with addition of Big River; Membership represents 11 production facilities and nearly 900 million gallons of ethanol capacity
4. In Comes the Non-Toxic Rust Remover; Rusterizer Presents Its Rust Removal Product Made With Natural Ingredients
5. Fusion presents low proliferation risk, experts conclude
6. Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
7. Cardium Presents First Quarter 2012 Financial Results and Recent Developments
8. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
9. ODT Forum Presents Regenerative Technologies
10. Fusion presents low proliferation risk, experts conclude
11. GeoVax Labs Presents New Findings on Potential HIV Vaccine at 2012 Conference on Retroviruses and Opportunistic Infections (CROI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... RURO, Inc., a leading LIMS, ... Limfinity® version 5.1.4. , RURO’s deployment teams have ... ever in RURO’s 8 year history. Many deployments ... Limfinity® version 5.1.4 is the perfect example – ... fixes! , Limfinity® 5.1.4 release highlights – more ...
(Date:11/22/2014)... , Nov. 21, 2014  The element of ... emerging diseases, i.e., they strike without warning. Until now, ... warning of a viral outbreak, resulting in suboptimal responses ... Ebola currently. Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... has now been removed because virus gene structural changes ...
(Date:11/21/2014)... 2014 The science of light and ... with more than 200 primary students in a traveling ... University of Otago Physics Department and funded by an ... members of the university’s OSA/SPIE Student Chapter visited six ... giving children from small, rural schools hands-on lessons in ...
(Date:11/21/2014)... 2014 The report, "Synthetic ... Enzymes, Cloning kits), Technology (Bioinformatics, Nanotechnology, Gene ... Biomaterials, Bioremediation) - Global Forecast to 2018", ... threats, opportunities, and challenges. , Browse 99 ... through 185 pages and in-depth TOC of ...
Breaking Biology Technology:RURO Announces Limfinity® version 5.1.4 2Viruses' Advantage of Surprise is Lost 2Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 2Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 3Synthetic Biology Market Expected to Reach $5,630.4 Million in 2018 - New Report by MarketsandMarkets 4
... interactive gene-level database to explore, understand, manage, and ... GenomeQuest, Inc., the leader in sequence data ... Digital Gene Expression Workflow designed to enable researchers ... Expression Workflow is the second such workflow to ...
... new Hospital Energy Performance Service can ... energy efficiency by 25% or more ... modifications. The service is available from Environmental ... environmental and engineering consulting firm."Healthcare facilities are heavy energy users ...
... 5 - Evoke Pharma, Inc., a privately-held specialty ... Phase 2b clinical trial to evaluate EVK-001 for the ... is a syndrome characterized by delayed emptying of the ... absence of mechanical obstruction. Diabetes is an important cause ...
Cached Biology Technology:GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform 2New Hospital Energy Performance Service Helps Hospitals Cut Energy Costs by 25% or More 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3
(Date:11/5/2014)... Brazil -Individuals show great diversity in their ability to ... females greatly differ in their perceptual evaluation of odors, ... tests. , Sex differences in olfactory detection ... may be connected to one,s perception of smell, which ... women,s olfactory superiority has been suggested to be cognitive ...
(Date:11/4/2014)... Fla. (November 4, 2014) — Think about the way ... How do neighboring cells know that they are supposed ... how do these tissues find the correct place and ... answering these crucial questions. , In a new study, ... to communicate with their surrounding neighbors, at the head-trunk ...
(Date:11/4/2014)... , Nov. 4, 2014   Neurotechnology ... today announced that the latest version of its ... the Ongoing MINEX evaluation organized by ... fingerprint algorithms using the INCITS 378 fingerprint standard ... requirement in public tenders in the ...
Breaking Biology News(10 mins):The female nose always knows: Do women have more olfactory neurons? 2The inside story: How the brain and skull stay together 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3
... of adults with autism has provided new evidence that ... may not communicate with each other as efficiently as ... University of Washington's Autism Center will report today at ... the first study that measures neural activity by using ...
... leading African-American lawmakers, civil rights leaders and medical ... adopt and implement a new blueprint to address ... The plan is outlined in a new report, ... the Epidemic in Black America, written by Robert ...
... from traditional radiation and chemotherapy treatment for head and ... good prognosis with treatment of p53 tumor suppressor gene ... test for a gene-based drug. , Researchers at Introgen ... advanced squamous cell carcinoma of the head and neck ...
Cached Biology News:Brain regions do not communicate efficiently in adults with autism 2New HIV statistics indicate increasing toll of AIDS on African American community 2New HIV statistics indicate increasing toll of AIDS on African American community 3New HIV statistics indicate increasing toll of AIDS on African American community 4Abnormal overexpression of p53 is a predictive molecular biomarker 2
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
... The membrane filters suitable for use in the ... top of each filter, in a specially designed ... special pleating of the band of membrane filter ... dispensed. The shape of the sealed band guarantees ...
...
Biology Products: